Supplementary Table 6. TEAEs of special interest

	Safety population (N=932) (Weeks 0-116)			
	IXE Q4W[a] N=454		IXE Q2W[a] N=518	
	n (%)	IR (95% CI) PY=713.3	n (%)	IR (95% CI) PY=885.6
Opportunistic infections	13 (2.9)	1.8 (1.1, 3.1)	13 (2.5)	1.5 (0.9, 2.5)
Candidiasis[b]	7 (1.5)	1.0 (0.5, 2.1)	4 (0.8)	0.5 (0.2, 1.2)
Herpes simplex	0	0.0 (0.0, 1.1)	3 (0.6)	0.3 (0.1, 1.1)
Herpes zoster	6 (1.3)	0.8 (0.4, 1.9)	6 (1.2)	0.7 (0.3, 1.5)
Injection-site reactions	53 (11.7)	7.4 (5.7, 9.7)	107 (20.7)	12.1 (10.0, 14.6)
Mild	40 (8.8)	5.6 (4.1, 7.6)	79 (15.3)	8.9 (7.2, 11.1)
Moderate	12 (2.6)	1.7 (1.0, 3.0)	23 (4.4)	2.6 (1.7, 3.9)
Severe	1 (0.2)	0.1 (0.0, 1.0)	5 (1.0)	0.6 (0.2, 1.4)
Allergic reactions /hypersensitivities	37 (8.1)	5.2 (3.8, 7.2)	46 (8.9)	5.2 (3.9, 6.9)
Cytopenia	8 (1.8)	1.1 (0.6, 2.2)	18 (3.5)	2.0 (1.3, 3.2)
Neutropenia	4 (0.9)	0.6 (0.2, 1.5)	8 (1.5)	0.9 (0.5, 1.8)
Hepatic events	34 (7.5)	4.8 (3.4, 6.7)	38 (7.3)	4.3 (3.1, 5.9)
Malignancies	3 (0.7)	0.4 (0.1, 1.3)	4 (0.8)	0.5 (0.2, 1.2)
Depression	6 (1.3)	0.8 (0.4, 1.9)	11 (2.1)	1.2 (0.7, 2.2)

[a]During COAST-X, 40 patients were switched from IXE Q4W to open-label IXE Q2W. Adverse events for these patients were counted for the dose regimen they were receiving when the AE occurred, thus these patients were counted in the total for both dose regimens. [b]None of the 11 candidiasis infections were systemic.
Abbreviations: IR, incidence rate per 100 patient-years; IXE, ixekizumab; PY, patient-years; Q2W, every 2 weeks; Q4W, every 4 weeks; TEAE, treatment-emergent adverse event.